SynAct Pharma: Term Sheet Signed for Brazil - Redeye
Redeye views the term sheet and potential for a commercial license agreement with Hipolabor as a logical extension of the clinical trial underway there. It proves there is potential in the second segment of resomelagon, infectious diseases.
ANNONS
Redeye views the term sheet and potential for a commercial license agreement with Hipolabor as a logical extension of the clinical trial underway there. It proves there is potential in the second segment of resomelagon, infectious diseases.